ANI Pharma (ANIP) Tops Q2 EPS by 34c; Boosts FY16 Outlook

ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $1.11, $0.34 better than the analyst estimate of $0.77. Revenue for the quarter came in at $31.34 million versus the consensus estimate of $27.63 million.

GUIDANCE:

ANI Pharma sees FY2016 EPS of $4.00-$4.25, versus the consensus of $3.63. ANI Pharma sees FY2016 revenue of $119-134 million, versus the consensus of $124.2 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge